Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.56 -4.1%	$2.02	$1.60 ▼ $2.77	$982.55M	1.01	1.75 million shs	8.54 million shs
ELDN Eledon Pharmaceuticals	$2.66 -1.8%	$3.15	$2.38 ▼ $5.54	$159.28M	-0.15	411,320 shs	602,715 shs
NUVB Nuvation Bio	$2.32 +3.6%	$2.20	$1.54 ▼ $3.45	$789.40M	1.35	4.18 million shs	4.26 million shs
PHVS Pharvaris	$21.09 +1.2%	$19.29	$11.51 ▼ $26.33	$1.10B	-2.81	78,249 shs	60,385 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+16.09%	+32.18%	+27.75%	+30.88%	+21.36%
ELDN Eledon Pharmaceuticals	0.00%	-16.62%	-20.76%	-6.55%	+3.44%
NUVB Nuvation Bio	-2.83%	-3.25%	+1.59%	+2.05%	-21.02%
PHVS Pharvaris	+3.58%	-1.88%	-17.04%	+29.36%	+29.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.4057 of 5 stars	0.0	5.0	2.5	0.0	1.3
ELDN Eledon Pharmaceuticals	2.2295 of 5 stars	3.5	2.0	3.0	1.7	0.0
NUVB Nuvation Bio	1.9723 of 5 stars	3.6	0.0	2.4	3.3	0.0
PHVS Pharvaris	1.8619 of 5 stars	3.5	2.0	1.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	3.00	Buy	$10.00	275.94% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	216.09% Upside
PHVS Pharvaris	3.00	Buy	$36.20	71.65% Upside

Current Analyst Ratings Breakdown

Latest ELDN, NUVB, CRON, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
7/25/2025	ELDN Eledon Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	8.35	N/A	N/A	$2.90 per share	0.88
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
NUVB Nuvation Bio	$7.87M	100.31	N/A	N/A	$1.37 per share	1.69
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.05	51.20	85.33	N/A	14.19%	-3.78%	-3.62%	N/A
ELDN Eledon Pharmaceuticals	-$36.18M	-$2.10	N/A	N/A	N/A	N/A	-79.54%	-41.62%	8/18/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	N/A
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)

Latest ELDN, NUVB, CRON, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	ELDN Eledon Pharmaceuticals	-$0.23	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q1 2025	PHVS Pharvaris	-$0.87	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	24.65	23.53
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
NUVB Nuvation Bio	0.13	9.39	9.38
PHVS Pharvaris	N/A	11.10	11.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
ELDN Eledon Pharmaceuticals	56.77%
NUVB Nuvation Bio	61.67%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
ELDN Eledon Pharmaceuticals	12.30%
NUVB Nuvation Bio	29.93%
PHVS Pharvaris	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	383.81 million	357.32 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable

ELDN, NUVB, CRON, and PHVS Headlines

Recent News About These Companies

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

2 hours ago | taiwannews.com.twT

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

2 hours ago | globenewswire.com

Pharvaris (PHVS) to Release Quarterly Earnings on Wednesday

August 12 at 2:51 AM | americanbankingnews.com

Pharvaris (PHVS) Projected to Post Earnings on Wednesday

August 6, 2025 | marketbeat.com

Analysts Set Pharvaris N.V. (NASDAQ:PHVS) PT at $36.20

August 5, 2025 | americanbankingnews.com

TD Asset Management Inc Has $1.23 Million Holdings in Pharvaris N.V. (NASDAQ:PHVS)

August 4, 2025 | marketbeat.com

Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Buy" by Brokerages

July 31, 2025 | marketbeat.com

Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions

July 27, 2025 | finance.yahoo.com

Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's What Happened

July 26, 2025 | marketbeat.com

Pharvaris secures $175 million public offering

July 25, 2025 | thepharmaletter.comT

Pharvaris shares slide following $175 million equity offering

July 25, 2025 | msn.com

Pharvaris Raises $201 Million in Successful Offering

July 24, 2025 | tipranks.com

Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What Happened

July 24, 2025 | marketbeat.com

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

July 22, 2025 | globenewswire.com

Pharvaris Announces Proposed Public Offering of Ordinary Shares

July 22, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Pharvaris (PHVS)

July 17, 2025 | theglobeandmail.com

Pharvaris (NASDAQ:PHVS) Stock Price Down 5.9% - Here's What Happened

July 15, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?

July 14, 2025 | marketbeat.com

Bank of America Securities Reaffirms Their Sell Rating on Pharvaris (PHVS)

July 12, 2025 | theglobeandmail.com

Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High - Here's What Happened

July 12, 2025 | marketbeat.com

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 ...

July 11, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, NUVB, CRON, and PHVS Company Descriptions

Cronos Group NASDAQ:CRON

$2.56 -0.11 (-4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 +0.00 (+0.20%)

As of 05:38 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.66 -0.05 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.68 +0.01 (+0.56%)

As of 05:36 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Nuvation Bio NYSE:NUVB

$2.32 +0.08 (+3.57%)

Closing price 03:59 PM Eastern

Extended Trading

$2.30 -0.02 (-0.69%)

As of 05:39 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharvaris NASDAQ:PHVS

$21.09 +0.25 (+1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$20.63 -0.46 (-2.18%)

As of 04:29 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time